Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Harpoon Therapeutics

Explore full profile

A clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases

South San Francisco, United StatesFounded 2015Biotech & Life Sciences
Valuation $100–500M Latest valuation · 2024
Revenue $10–50M Latest reported FY
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding

About Harpoon Therapeutics

Harpoon Therapeutics is a biotechnology company specializing in the development of novel immuno-oncology treatments. The company operates in the biopharmaceutical market, focusing on creating innovative therapies that engage T cells to target and destroy cancer cells. Harpoon's proprietary technology platform, known as TriTAC (Tri-specific T cell Activating Construct), is designed to harness the body's immune system to fight cancer and other serious diseases. The company primarily serves patients with cancer, aiming to provide new treatment options through its cutting-edge biologics. Harpoon Therapeutics generates revenue through partnerships, licensing agreements, and the development and commercialization of its proprietary therapies. Notably, Harpoon has an exclusive worldwide option and license agreement with AbbVie for HPN217, a BCMA-targeting TriTAC, and is expanding its discovery collaboration to include up to six additional targets.

Source: Dealroom company data

At a glance

Founded
2015
Headquarters
South San Francisco, United States
Listing
IPO 2019
Sector
Biotech & Life Sciences
Power Law
Colt$25–100M revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • MPM BioImpact
  • Arix Bioscience
  • New Leaf Venture Partners
  • Taiho Pharma

Series B and later2 investors entered at this stage

Talent

Book a demo to see the people
Team profiled 15 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · South San Francisco HQ
Book a demo for the full country breakdown
Web traffic by country
350 monthly visits
across markets
🇺🇸 United States85.7%
🇿🇦 South Africa0%
🇹🇼 Taiwan0%
Top 3 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Harpoon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Harpoon Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles